Astrazeneca Pharma India Ltd

Astrazeneca Pharma India announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 36 per equity Share (i.e. 1800%) , subject to the approval of the shareholders.

Net profit of Astrazeneca Pharma India declined 22.95% to Rs 44.88 crore in the quarter ended March 2026 as against Rs 58.25 crore during the previous quarter ended March 2025. Sales rose 20.42% to Rs 578.61 crore in the quarter ended March 2026 as against Rs 480.48 crore during the previous quarter ended March 2025. For the full year,net profit rose 62.02% to Rs 187.52 crore in the year ended March 2026 as against Rs 115.74 crore during the previous year ended March 2025. Sales rose 32.59% to Rs 2275.58 crore in the year ended March 2026 as against Rs 1716.29 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales578.61480.48 20 2275.581716.29 33 OPM %10.5317.98 -11.5114.80 - PBDT64.82101.84 -36 286.03293.14 -2 PBT59.2284.15 -30 257.45253.15 2 NP44.8858.25 -23 187.52115.74 62 Powered by Capital Market - Live

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 26 May 2026.

Through this approval, Acalabrutinib tablets 100 mg in combination with venetoclax with or without obinutuzumab is indicated for the treatment of patients with previously untreated chronic lymphocytic leukaemia (CLL) /small lymphocytic lymphoma (SLL). This regulatory clearance paves the way for the commercial launch and availability of Calquence in the Indian market. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit declined 42.3% to Rs 31.55 crore despite 38.9% increase in net sales to Rs 615.57 crore in Q3 FY26 over Q3 FY25. The counter advanced 1.45% to end at Rs 8,291.50 on Friday, 10 April 2026.

Astrazeneca Pharma India announced that Jes's Diaz-Ropero Esteso has resigned from the position of Non-Executive Director of AstraZeneca Pharma India and consequently from the Board Committee(s) on which he served, with immediate effect, due to a transition from current responsibilities. Powered by Capital Market - Live

Net profit of Astrazeneca Pharma India rose 5.64% to Rs 32.59 crore in the quarter ended December 2025 as against Rs 30.85 crore during the previous quarter ended December 2024. Sales rose 38.90% to Rs 611.57 crore in the quarter ended December 2025 as against Rs 440.29 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales611.57440.29 39 OPM %7.3317.49 - PBDT48.9084.64 -42 PBT45.0675.57 -40 NP32.5930.85 6 Powered by Capital Market - Live

Astrazeneca Pharma India will hold a meeting of the Board of Directors of the Company on 11 February 2026.Powered by Capital Market - Live

This authorization from the Central Drugs Standard Control Organization (CDSCO) marks the introduction of this treatment as a new drug in the Indian market. This approval allows Datverzo to be used for treating adult patients with specific types of advanced, hormone-receptor-positive and HER2-negative breast cancer. The treatment is intended for those who have already undergone endocrine-based therapy and chemotherapy for disease that is either metastatic or cannot be surgically removed. The receipt of this permission paves way for the marketing of Datopotamab Deruxtecan powder for the specified indication, subject to the receipt of related statutory approvals, if any. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit shed 2.88% to Rs 54.22 crore in Q2 FY26 as against Rs 55.83 crore posted in Q1 FY26. Revenue from operations rose 6.22% QoQ to Rs 559.09 crore in the quarter ended 30 September 2025. On a year on year (YoY) basis, the company's net profit surged 41.08% while revenue from operations increased 37.03% in Q2 FY26. The scrip shed 0.36% to currently trade at Rs 8993 on the BSE. Powered by Capital Market - Live

The agreement aims to accelerate access to SZC, an innovative treatment for hyperkalaemia, across the country. Hyperkalaemia, a clinically significant condition, disproportionately affects patients with chronic kidney disease (CKD) and heart failure (HF) receiving RAAS inhibitor therapy, which can elevate serum potassium levels. Studies indicate that the condition occurs in up to 50% of CKD patients and 42% of chronic HF patients. Under the pact, both companies will promote, market, and distribute SZC under different brand names'AstraZeneca as Lokelma and Sun Pharma as Gimliand. AstraZeneca will retain intellectual property rights, marketing authorization, and the import license for the therapy. This partnership marks a strategic step to expand patient access to SZC in India while leveraging the marketing and distribution networks of both companies. Praveen Rao Akkinepally, Country president & MD, AstraZeneca Pharma India said, 'At AstraZeneca, we aim to transform care with a focus on increasing early screening, diagnosis, and adoption of guideline-directed medical therapy to improve patient outcomes. This partnership with Sun Pharma for SZC reaffirms AstraZeneca's purpose to deliver innovative, life-changing medicines to patients with Hyperkalaemia across India, coupled with building robust pathways to reach patients in need. With this step, we are poised to significantly expand the reach of this vital therapy and help address the disease burden'. Kirti Ganorkar, MD, Sun Pharmaceutical Industries, said, 'We are delighted to join hands with AstraZeneca to address the growing challenge of Hyperkalaemia in India. The addition of SZC to our portfolio underscores our unwavering commitment to improving the care of patients with chronic kidney disease. As India's largest pharmaceutical company and a leader in this therapy area, we remain focused on expanding access to innovative treatments that empower healthcare professionals and enhance the quality of life for patients.' AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries. The company's standalone net profit shed 2.88% to Rs 54.22 crore in Q2 FY26 as against Rs 55.83 crore posted in Q1 FY26. Revenue from operations rose 6.22% QoQ to Rs 559.09 crore in the quarter ended 30 September 2025. On a year on year (YoY) basis, the company's net profit surged 41.08% while revenue from operations increased 37.03% in Q2 FY26. Shares of AstraZeneca Pharma India rose 0.20% to Rs 9,158.50, while Sun Pharmaceutical Industries declined 0.50% to Rs 1,755.10 on the BSE. Powered by Capital Market - Live

Astrazeneca Pharma India and Sun Pharmaceutical Industries announced a second brand partnership for Sodium Zirconium Cyclosilicate (SZC) in India. This exclusive agreement is aimed at further accelerating availability of SZC, an innovative and highly effective treatment for Hyperkalaemia to more patients across India. Under the agreement, both companies will promote, market AstraZeneca will market SZC as Lokelma' whereas Sun Pharma will promote and distribute the therapy as Gimliand'. AstraZeneca will retain the intellectual property rights to SZC and hold the Marketing Authorisation along with the import license of the molecule. Powered by Capital Market - Live